biostudies-literatureCervia CSchweizerische Akademie der Medizinischen WissenschaftenSwiss National Science FoundationGottfried und Julia Bangerter-Rhyner-Stiftung (Bangerter-Stiftung)Schweizerische Akademie der Medizinischen Wissenschaften (Swiss Academy of Medical Sciences)University of Zurich (UZH Forschungskredit CandocGottfried und Julia Bangerter-Rhyner-StiftungClinical Research Priority Program CYTIMM-Z of University of Zurich (UZH), Pandemic Fund of University of Zurich (UZH), Innovation grant of University Hospital Zurich446https://www.ebi.ac.uk/biostudies/studies/S-EPMC8789854biostudies-literatureUnknown13(1)Following acute infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) a significant proportion of individuals develop prolonged symptoms, a serious condition termed post-acute coronavirus disease 2019 (COVID-19) syndrome (PACS) or long COVID. Predictors of PACS are needed. In a prospective multicentric cohort study of 215 individuals, we study COVID-19 patients during primary infection and up to one year later, compared to healthy subjects. We discover an immunoglobulin (Ig) signature, based on total IgM and IgG3 levels, which - combined with age, history of asthma bronchiale, and five symptoms during primary infection - is able to predict the risk of PACS independently of timepoint of blood sampling. We validate the score in an independent cohort of 395 individuals wNature communicationsImmunoglobulin signature predicts risk of post-acute COVID-19 syndrome.PMC8789854323530-177975310030-200669YTCR 32/18NRP 78 Implementation Programme323530-191220323530-1912304078P0-198431Rudiger AMenges DBachli ENilsson JZurbuchen YTaeschler PRaeber MEAdamo SHeld UBoyman OHuber LCPuhan MACervia CHasler SStussi-Helbling MBallouz TfalseImmunoglobulin signature predicts risk of post-acute COVID-19 syndrome.Following acute infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) a significant proportion of individuals develop prolonged symptoms, a serious condition termed post-acute coronavirus disease 2019 (COVID-19) syndrome (PACS) or long COVID. Predictors of PACS are needed. In a prospective multicentric cohort study of 215 individuals, we study COVID-19 patients during primary infection and up to one year later, compared to healthy subjects. We discover an immunoglobulin (Ig) signature, based on total IgM and IgG3 levels, which - combined with age, history of asthma bronchiale, and five symptoms during primary infection - is able to predict the risk of PACS independently of timepoint of blood sampling. We validate the score in an independent cohort of 395 individuals w2022-01-01T00:00:00Z2022 Jan2025-04-04T14:59:05.409Z2025-04-04T14:59:05.409ZS-EPMC87898543507898210.1038/s41467-021-27797-1